KRAS and colorectal carcinoma: Moreover, a recent subgroup analysis of the Keynote 177 trial showed a differential effect of anti-PD1 therapy according to RAS mutational status, suggesting a lack of benefit among patients with mutated KRAS (mKRAS) CRC [14].